A multicentre, open, uncontrolled phase IIIb study to evaluate the efficacy and safety of Etanercept 0.8 mg/kg body weight (bw) given once weekly to patients with polyarticular-course juvenile idiopathic arthritis (JIA) for 12 weeks
Latest Information Update: 14 Aug 2014
At a glance
- Drugs Etanercept (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- 10 Aug 2012 New trial record